FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological ...
Morning Overview on MSN
New prostate cancer immunotherapy slashes biomarkers by up to 99%
An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...
PSA 10 autographed cards of MLB Hall of Famer Gary Sheffield continue to attract collectors at all levels thanks to his ...
Background Psoriatic disease has a complex effect on bone metabolism, resulting in both pathological bone formation and bone resorption. However, microstructural changes in cortical and trabecular ...
A meta-analysis seeks to determine if adding hormone therapy to radiotherapy after prostatectomy improves overall survival.
It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.
The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...
11d
Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, study finds
A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men ...
A study released by the Lake Commission found the current management of Lake Pend Oreille has left the region’s economy 10% to 11% smaller than it could be. Conducted by two professors from the ...
SYDNEY, Feb. 16, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...
A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results